MAPK3 and kidney disorder: Our results showed that ERK1/2 were activated in the kidney of hyperuricemic nephropathy and pharmacological blockade of ERK1/2 activation with U0126 improved renal function, decreased urine microalbumin, attenuated pathological changes, inhibited activation of renal interstitial fibroblasts and decreased accumulation of extracellular matrix proteins in the hyperuricemic kidney.